

**GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA
UNSTARRED QUESTION No. 2157
TO BE ANSWERED ON THE 31st July, 2018

Orphan Drugs

2157. ADV. NARENDRA KESHAV SAWAIKAR:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) whether it is a fact that NITI Aayog has recommended exemption of 'orphan drugs' and unbranded generic drugs from price control;
- (b) if so, the details thereof;
- (c) whether the National Pharmaceutical Pricing Authority (NPPA) has considered the views of the NITI Aayog, if so, the details and outcome thereof; and
- (d) whether the Government is ensuring that such a decision would not have an adverse impact on the society, particularly with regard to orphan drugs?

ANSWER

**MINISTER OF STATE IN THE MINISTRY OF ROAD TRANSPORT AND HIGHWAYS;
MINISTRY OF SHIPPING AND MINISTRY OF CHEMICALS AND FERTILIZERS
(SHRI MANSUKH L. MANDAVIYA)**

(a) to (d): The National Pharmaceutical Pricing Authority (NPPA) has suggested certain amendments to the Drugs (Prices Control) Order, 2013 (DPCO-2013). During stakeholder consultations on the same, NITI Aayog has recommended that orphan drugs and unbranded generic drugs should be included in the ambit of para 32 of DPCO-2013 which gives exemption to certain categories of drugs from price control. The final view on the same is taken after consulting all the stakeholders and on the merits of the proposals with overall public interest in view which is an ongoing process.

XXXXX